Filing Flows › Co-Diagnostics (CODX) › Q1 2025
Co-Diagnostics (CODX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Co-Diagnostics (CODX) reported revenue of $50K for the first quarter 2025 (Q1 2025), -89% from a year earlier and -66% from the quarter before.
Co-Diagnostics, Q1 2025: revenue $50K (-89% year over year), net loss $7.5M, operating cash flow −$8.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $50K | -66% | -89% |
| Operating profit | −$8.6M | — | — |
| Net earnings | −$7.5M | — | — |
| Operating cash flow | −$8.7M | — | — |
What changed
Revenue was $50K in Q1 2025, down 89% year over year and down 66% from the previous quarter.
Gross margin was 57.1%, up 7.2 points from a year earlier. Operating costs exceeded revenue by $8.6M, an operating margin of -17009.7%. Operating expenses fell 18% while revenue fell 89%. The quarter ended with a net loss of $7.5M, narrower than the previous quarter's $11.0M loss.
Operating cash flow was −$8.7M. Non-cash charges added back $280K of depreciation and amortization and $875K of share-based compensation. Working capital and other items used $2.4M. Capital expenditures of $92K exceeded it, leaving free cash flow of −$8.8M.
Questions
What was Co-Diagnostics' revenue in the first quarter 2025?
Co-Diagnostics (CODX) reported revenue of $50K for the first quarter 2025 (Q1 2025), -89% from a year earlier and -66% from the quarter before.
Source: Co-Diagnostics 10-Q on SEC EDGAR.